{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:10:45Z","timestamp":1779970245082,"version":"3.53.1"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100014931","name":"Arrowhead Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014931","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Plozasiran (Redemplo), a novel small interfering RNA (siRNA) therapeutic targeting the hepatic biosynthesis of apolipoprotein C\u2010III (APOC3), is approved by the US FDA for treating familial chylomicronemia syndrome (FCS), a disease of rare prevalence that presents with extremely elevated levels of serum triglycerides (TG) leading to a higher risk of acute pancreatitis. Plozasiran is also in Phase 3 development to treat the broader indication of severe hypertriglyceridemia. Population pharmacodynamic (PD) analysis of plozasiran was conducted on serially measured serum APOC3 and TG levels in the FCS patients participating in the pivotal Phase 3 study by employing a cascading kinetic\u2010PD model that described the inhibitory effect of plozasiran on the synthesis of APOC3, which in turn decreases serum TG levels. The estimated IC\n                    <jats:sub>50<\/jats:sub>\n                    dose of plozasiran was 2.2 mg, demonstrating potent on\u2010target pharmacological activity of plozasiran conferred by its efficient mechanism of action via RNA interference (RNAi). The model\u2010estimated elimination half\u2010life of plozasiran in the liver was 48 days, supporting quarterly dosing (Q3M) for patients\u2019 convenience. Body mass index (BMI) and background TG\u2010lowering therapy were identified as the only statistically significant covariates without clinical importance, and the subcutaneous 25 mg Q3M dose is approved for all adult FCS patients, including those with Asian ethnicity, mild\u2010to\u2010moderate degrees of renal impairment or a mild degree of hepatic impairment. There was no evidence to suggest that the TG\u2010lowering efficacy of plozasiran was significantly different between clinically diagnosed and genetically confirmed FCS patients, and therefore plozasiran treatment is suitable for both genetic and clinically diagnosed FCS patients.\n                  <\/jats:p>","DOI":"10.1002\/jcph.70190","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:50:05Z","timestamp":1776664205000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome"],"prefix":"10.1002","volume":"66","author":[{"given":"James","family":"Ousey","sequence":"first","affiliation":[{"name":"Arrowhead Pharmaceuticals  Pasadena CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie H","family":"Gosselin","sequence":"additional","affiliation":[{"name":"Certara Drug Development Solutions  Radnor PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh","family":"Ta","sequence":"additional","affiliation":[{"name":"Arrowhead Pharmaceuticals  Pasadena CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2919-9115","authenticated-orcid":false,"given":"Jack","family":"Shi","sequence":"additional","affiliation":[{"name":"Arrowhead Pharmaceuticals  Pasadena CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.03.013"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(13)70191\u20108"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP\u20102018\u20100157"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.06.814"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11883\u2010023\u201001080\u20108"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2024.13.1.2"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200325"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404143"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.0959"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2412616"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.122.001107"},{"key":"e_1_2_7_14_1","unstructured":"Clinical pharmacology considerations for the development of oligonucleotide therapeutics: guidance for industry. US Food and Drug Administration Center for Drug Evaluation and Research. June 2024. Accessed December 5 2025.https:\/\/www.fda.gov\/media\/159414\/download"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2418"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.118.015750"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928\u2010006\u20109035\u2010z"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.70055"},{"key":"e_1_2_7_19_1","unstructured":"<number>18.Multi\u2010discipline review for 212194Orig1s000. US Food and Drug Administration Center for Drug Evaluation and Research. Accessed April 24 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212194Orig1s000MultidisciplineR.pdf"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2774"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70190","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.70190","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:55:27Z","timestamp":1779969327000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/jcph.70190"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70190","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70190"}}